View downloadable slides from our satellite symposium in Barcelona for professionals involved in the treatment of patients with metastatic pancreatic cancer (mPCA). Get the latest updates on the emerging treatment approaches for targeting the pancreatic tumor microenvironment and strategies to enhance immune response.
Jun 25, 2018
Jun 25, 2019
- Teresa Macarulla, MD, PhD, Vall d’Hebron University Hospital, Barcelona, Spain
Considering treatment options for advanced PCA in light of new data: What is the optimal treatment sequence?
- Eileen O’Reilly, MD, Memorial Sloan Kettering Cancer Center, New York, New York, United States
Overcoming treatment resistance in PCA: Update on emerging strategies targeting the tumor microenvironment
- Giuseppe Aprile, MD, San Bortolo General Hospital, Vicenza, Italy
Supportive care across the disease continuum: An important adjunct to systemic therapy
- Julien Taïeb, MD, PhD, Georges Pompidou European Hospital, Paris, France,
This educational activity is designed for medical oncologists, gastroenterologists, and other healthcare providers outside of the United States who are involved in the management of patients with PCA.
After successful completion of this educational activity, participants should be able to:
- Select the most appropriate treatment sequence for patients with advanced pancreatic ductal adenocarcinoma, taking into consideration patient and disease characteristics
- Describe emerging treatment approaches for targeting the PCA microenvironment, including stromal depleting agents and strategies to enhance immune response
- Evaluate and appropriately use supportive care measures in patients with PCA
This educational activity is supported by a grant from Shire.
Independent Medical Education (IME)
This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.t.
This activity is provided by prIME Oncology.
Disclosure of Relevant Financial Relationships
prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of IME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality IME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:
Dr Aprile has disclosed that he received honoraria for promotional speakers’ bureaus from Amgen, Bayer, Celgene, Lilly, Merck, Roche, Sanofi, and Servier. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Macarulla has no relevant financial relationships to disclose. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.
Dr O’Reilly has disclosed that she received consulting fees from Agios, Amgen, Antengene, Aptus, Aslan, Astellas, AstraZeneca, Bayer, Boston Scientifc, Bristol-Myers Squibb, Carsgen, Casi, Celgene, CytomX, Daiichi, Debio, Delcath, Eisai, Exelixis, Gilead, Halozyme, Inovio, Ipsen, Merck, Onxeo, PCI Biotech, Roche, Sanofi, Servier, Silenseed, Sillajen, Sirtex, Vicus, and Yakult. She is also independently contracted by Agios, Array, AstraZeneca, Bayer, Bristol-Myers Squibb, Casi, Celgene, Exelixis, Genentech, Incyte, Lilly, Mabvax, Medimmune, Momenta, Novartis, OncoMed Pharmaceuticals, and Roche. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.
Dr Taïeb has disclosed that he received honoraria for advisory or speaker roles from Amgen, Celgene, Lily, Merck, MSD, Roche, Sanofi, Servier, Shire, and Sirtex. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
The employees of prIME Oncology have disclosed:
- Bojana Pajk, MD, MSc (medical director content reviewer/planner) – no relevant financial relationships
- Sanneke Koekkoek, RN (scientific content reviewer/planner) – no relevant financial relationships
- Jessica Mastrodomenico, MPH (editorial content reviewer) – no relevant financial relationships
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.